Washington Saturday, September 12, 2015, 17:00 Hrs [IST] |
Vanda Pharmaceuticals Inc. (Vanda), a biopharmaceutical company, announced that a favourable Markman ruling has been issued by the United States District Court for the District of Delaware in the patent infringement lawsuit filed by the company against Roxane Laboratories Inc. (Roxane) regarding Roxane’s submission of an Abbreviated New Drug Application to make and sell a generic version of Fanapt, schizophrenia drug.A Markman ruling, also known as a Claim Construction Ruling, is a court ruling in which the judge determines the meaning of key terms from certain disputed patent claims. The Delaware court, which was asked to construe disputed patent claim terms in US patent number 8,586,610 (‘610), rejected Roxane’s proposed construction of all the disputed claim terms. The ‘610 patent is expected to expire in November 2027.Fanapt is an atypical antipsychotic agent indicated for treatment of schizophrenia in adults. In choosing among treatments, prescribers should consider the ability of Fanapt to prolong the QT interval and the use of other drugs first. Prescribers should also consider the need to titrate Fanapt slowly to avoid orthostatic hypotension, which may lead to delayed effectiveness compared to some other drugs that do not require similar titration. |
Vanda gets favorable Markman ruling in Fanapt patent infringement litigation
-
Why orphan drug coverage reimbursement decision-makingneeds patient and public involvement
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0168851015000123-mainDownload
-
Drug patents are Bad for your health: the cost of mismarketing – By Dean Baker
Pharma Live, , Intellectual Property Rights, 0
The rationale for granting patents for new drugs is to give companies incentives to research new and better drugs....
-
RCEs and the New USPTO Patent Term Adjustment Rules – Courtesy (Global IP Matters)
Pharma Live, , Intellectual Property Rights, 0
On January 9, 2015, the Federal Register published final rules implementing changes to patent term adjustment (PTA) in view of Novartis v....
-
To Study The Scope & Importance Of Amended Patent Act On Indian Pharmaceutical Company With Respect To Innovation
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s2212567114002469-mainDownload
-
Pfizer Trying To Overcome Patent Cliff – Courtesy (Seeking Alpha)
Pharma Live, , Intellectual Property Rights, 0
Pfizer Inc. (NYSE:PFE) is trying to overcome the patent cliff that has seen its recent quarter results suffer by...
-
Sanders Asks VA to Break Patents on Gilead and AbbVie Hep C Drugs – Courtesy(Pharmalot)
Pharma Live, , Intellectual Property Rights, 0
The ongoing debate over the cost of prescription drugs took another twist as U.S. Sen. Bernie Sanders (I-VT.) has...
-
Frequently Asked Questions on Patents and Exclusivity
Pharma Live, , Intellectual Property Rights, 0
What is the difference between patents and exclusivity? Patents and exclusivity work in a similar fashion but are distinctly...
-
Gene Associated with ALS identified ! – Courtesy(Patent Docs)
Pharma Live, , Intellectual Property Rights, 0
One of the promises of the Human Genome Project was that knowledge of the entirety of the human genetic...
![](https://ml7mn4k5dnn0.i.optimole.com/w:289/h:289/q:eco/f:best/https://interactivepharm.com/wp-content/uploads/2022/08/Show-your.jpg)